The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Chronic Toxicity and Carcinogenicity Studies of the Long-Acting GLP-1 Receptor Agonist Dulaglutide in Rodents
Abstract
The tumorigenic potential of dulaglutide was evaluated in rats and transgenic mice. Rats were injected sc twice weekly for 93 weeks with dulaglutide 0, 0.05, 0.5, 1.5, or 5 mg/kg corresponding to 0, 0.5, 7, 20, and 58 times, respectively, the maximum recommended human dose based on plasma area under the curve. Transgenic mice were dosed sc twice weekly with dulaglutide 0, 0.3, 1, or 3 mg/kg for 26 weeks. Dulaglutide effects were limited to the thyroid C-cells. In rats, diffuse C-cell hyperplasia and adenomas were statistically increased at 0.5 mg/kg or greater (P ≤ .01 at 5 mg/kg), and C-cell carcinomas were numerically increased at 5 mg/kg. Focal C-cell hyperplasia was higher compared with controls in females given 0.5, 1.5, and 5 mg/kg. In transgenic mice, no dulaglutide-related C-cell hyperplasia or neoplasia was observed at any dose; however, minimal cytoplasmic hypertrophy of C cells was observed in all dulaglutide groups. Systemic exposures decreased over time in mice, possibly due to an antidrug antibody response. In a 52-week study designed to quantitate C-cell mass and plasma calcitonin responses, rats received twice-weekly sc injections of dulaglutide 0 or 5 mg/kg. Dulaglutide increased focal C-cell hyperplasia; however, quantitative increases in C-cell mass did not occur. Consistent with the lack of morphometric changes in C-cell mass, dulaglutide did not affect the incidence of diffuse C-cell hyperplasia or basal or calcium-stimulated plasma calcitonin, suggesting that diffuse increases in C-cell mass did not occur during the initial 52 weeks of the rat carcinogenicity study.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The association between GLP-1 RAs and MTC in humans has not been proven, and studies have shown interspecies differences regarding the density of GLP-1 receptors and responses to GLP-1 RA activation in the thyroid, limiting the predictive value of nonhuman preclinical studies on humans.23,24,46”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [24]
In the citing paper
“The association between GLP-1 RAs and MTC in humans has not been proven, and studies have shown interspecies differences regarding the density of GLP-1 receptors and responses to GLP-1 RA activation in the thyroid, limiting the predictive value of nonhuman preclinical studies on humans.23,24,46”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [24]
In the citing paper
“Pharmacological studies in rodents support an association between the use of GLP-1 RAs and the development of medullary thyroid cancer (MTC) resulting in a black box warning for these agents in patients at risk for this condition.”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [24]
Citations
Cites
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · cited 7×
“With respect to studies in other species, in the nonhuman primate studies of liraglutide (5), no changes in 2426 Byrd et al Dulaglutide Thyroid Tumors in Rats Endocrinology, July 2015, 156(7):2417–2428”
InfluentialPeto, R., Pike, M. C., Day, N., Gray, R. G., Lee, P. N., Parish, S., Peto, J., Richards, S. M., & Wahrendorf, J. (1980) · PubMed · Cited by 478
GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
Korner, M., Stockli, M., Waser, B., & Reubi, J. C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038679 · Cited by 477 · cited 2×
“Available data from preclinical investigative approaches regarding GLP-1 receptor agonists and thyroid C-cell effects have largely focused on species differences in GLP-1 receptor expression in C cells (5, 29).”
Tests for trend in life table analysis
TARONE, R. E. (1975) · Biometrika · doi:10.1093/biomet/62.3.679 · Cited by 412
Panjwani, N., Mulvihill, E. E., Longuet, C., Yusta, B., Campbell, J. E., Brown, T. J., Streutker, C., Holland, D., Cao, X., Baggio, L. L., et al. (2013) · Endocrinology · doi:10.1210/en.2012-1937 · Cited by 346 · cited 1×
“Some uncertainty remains regarding the specificity of the antibodies available for detection of the GLP-1 receptor (31, 32).”
Glaesner, W., Mark Vick, A., Millican, R., Ellis, B., Tschang, S., Tian, Y., Bokvist, K., Brenner, M., Koester, A., Porksen, N., et al. (2010) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1080 · Cited by 305
A Critical Analysis of the Clinical Use of Incretin-Based Therapies
Butler, P. C., Elashoff, M., Elashoff, R., & Gale, E. A. M. (2013) · Diabetes Care · doi:10.2337/dc12-2713 · Cited by 296
Trend and homogeneity analyses of proportions and life table data
Thomas, D. G., Breslow, N., & Gart, J. J. (1977) · Computers and Biomedical Research · doi:10.1016/0010-4809(77)90006-4 · Cited by 225
Cited by
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer
Bezin, J., Gouverneur, A., Pénichon, M., Mathieu, C., Garrel, R., Hillaire-Buys, D., Pariente, A., & Faillie, J.-L. (2023) · Diabetes Care · doi:10.2337/dc22-1148 · Cited by 320
Varin, E. M., Mulvihill, E. E., Baggio, L. L., Koehler, J. A., Cao, X., Seeley, R. J., & Drucker, D. J. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.055 · Cited by 104
Vallöf, D., Kalafateli, A. L., & Jerlhag, E. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-00923-1 · Cited by 80
Bea, S., Son, H., Bae, J. H., Cho, S. W., Shin, J., & Cho, Y. M. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15292 · Cited by 64
Epigenetic and Transcriptional Regulation of IRAK-M Expression in Macrophages
Lyroni, K., Patsalos, A., Daskalaki, M., Doxaki, C., Sönnichsen, B., Helms, M. W., Liapis, I., Zacharioudaki, V., Kampranis, S. C., & Tsatsanis, C. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600009 · Cited by 42
Metadata
- Authors
- Byrd, R. A., Sorden, S. D., Ryan, T., Pienkowski, T., LaRock, R., Quander, R., Wijsman, J. A., Smith, H. W., Blackbourne, J. L., Rosol, T. J., Long, G. G., Martin, J. A., & Vahle, J. L.
- Affiliations
- Eli Lilly (United States) (US)
- Covance (United States) (US)
- The Ohio State University (US)
- Experimental Pathology Laboratories (US)
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2015-04-10
- Volume
- 156
- Issue
- 7
- Pages
- 2417-2428
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2003463625
- Cited by
- 36
- References
- 26
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 3 · 2023: 8 · 2022: 2 · 2021: 1 · 2020: 1 · 2019: 2 · 2017: 2 · 2016: 4 · 2015: 2
- FWCI
- 2.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Carcinogens and Genotoxicity Assessment
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Keywords
- dulaglutide, GLP-1 receptor agonists, thyroid adenoma, carcinogenicity, chronic toxicity, transgenic mice, rats, calcitonin
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Animals, Calcitonin, Glucagon-Like Peptides, Female, Hyperplasia, Hypoglycemic Agents, Immunoglobulin Fc Fragments, Male, Mice, Transgenic, Organ Size, Recombinant Fusion Proteins, Thyroid Gland, Thyroid Neoplasms, Carcinogenicity Tests, Proto-Oncogene Proteins p21(ras), Receptors, Glucagon, Carcinoma, Neuroendocrine, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chronic Toxicity and Carcinogenicity Studies of the Long-Acting GLP-1 Receptor Agonist Dulaglutide in Rodents. https://app.cochat.ai/papers/10.1210/en.2014-1722
- The paper
- Byrd, R. A., Sorden, S. D., Ryan, T., Pienkowski, T., LaRock, R., Quander, R., Wijsman, J. A., Smith, H. W., Blackbourne, J. L., Rosol, T. J., Long, G. G., Martin, J. A., & Vahle, J. L. (2015). Chronic Toxicity and Carcinogenicity Studies of the Long-Acting GLP-1 Receptor Agonist Dulaglutide in Rodents. Endocrinology. https://doi.org/10.1210/en.2014-1722
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.